vector
securities
analyst
michael
king
said
started
biochem
pharma
buy
rating
shares
biopharmaceutical
firm
60.50
toronto
stock
exchange
biochem
pharma
experience
explosive
growth
sales
earnings
3-5
years
king
said
chicago
newsdesk
312-408-8787
